Common Warts Market Report 2026

The common warts market size has grown strongly in recent years. It will grow from $2.25 billion in 2025 to $2.38 billion in 2026 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to increasing prevalence of hpv infections, widespread use of cryotherapy treatments, availability of topical salicylic acid products, growth of dermatology clinics, improved awareness of skin health.

The common warts market size is expected to see strong growth in the next few years. It will grow to $2.96 billion in 2030 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to increasing demand for non-invasive dermatological treatments, rising focus on cosmetic dermatology solutions, expansion of homecare dermatology products, growing adoption of laser-based therapies, increasing investment in immunomodulatory treatments. Major trends in the forecast period include advancements in minimally invasive wart removal techniques, rising adoption of combination therapy approaches, increased availability of over-the-counter treatments, growing use of immunotherapy-based topicals, expansion of home-based treatment options.

The rising incidence of viral infections is expected to drive the growth of the common warts market in the coming years. Viral infections are illnesses caused by viruses that enter the body, replicate, and spread, affecting cells and immune system responses. The increasing occurrence of viral infections is influenced by factors such as globalization, climate change, urbanization, deforestation, and weakened immune function. Treatments for common warts specifically target the human papillomavirus responsible for wart development and support patients by limiting viral spread, easing discomfort, and promoting healing. These treatments also help prevent complications such as secondary infections or scarring while improving overall quality of life. For example, in 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, the proportion of PCR-confirmed varicella cases increased by 62% between 2017 and 2022, rising from 29% to 47%. Additionally, in January 2023, according to the National Foundation for Infectious Diseases, a US-based health organization, an estimated 14 million new human papillomavirus infections occur annually in the United States. As a result, the growing burden of viral infections is contributing to the expansion of the common warts market.

Major companies operating in the common warts market are increasingly focused on advancing innovative treatments, including dermatological therapies, to address the rising demand for effective and accessible solutions. These efforts aim to enhance patient outcomes and strengthen market presence within the dermatology segment. Dermatological therapies encompass treatments used to manage skin-related conditions such as infections, inflammatory disorders, and other dermatologic diseases. For instance, in May 2024, Verrica Pharmaceuticals, a US-based pharmaceutical company, entered into a licensing agreement with Torii Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, to support a global Phase 3 clinical trial for YCANTH, a treatment for common warts. Under this agreement, Torii Pharmaceutical will provide funding to advance the late-stage development of YCANTH, expanding its potential global reach. This collaboration enhances both companies’ dermatology portfolios and international market positions.

In June 2023, Vial, a US-based clinical trial management organization, partnered with Nielsen BioSciences to conduct a Phase 3 clinical trial for CANDIN as a treatment for common warts. This collaboration is intended to advance the development of CANDIN by evaluating its safety and effectiveness. Nielsen BioSciences, a US-based biotechnology company specializing in immune-based therapies, is contributing to the effort by supporting the progression of CANDIN as a promising therapeutic option for common warts.

Major companies operating in the common warts market are GSK plc, Perrigo Company plc, Holland & Barrett International Limited, Prestige Consumer Healthcare Inc., Novan Inc., Aclaris Therapeutics Inc., Verrica Pharmaceuticals Inc., Scholl’s Wellness Company, Naturasil, Bausch Health Companies Inc., Viatris Inc., Sanofi S.A., Pfizer Inc., Bayer AG, Novartis AG, Dr Reddy’s Laboratories Ltd, Cipla Inc, Taro Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, AIM ImmunoTech Inc, Phio Pharmaceuticals Corp, Euro Vital Pharma GmbH, Koninklijke Utermöhlen NV, Lumenis Be Ltd, Almirall S.A, Daiichi Sankyo Company Ltd.

North America was the largest region in the common warts market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the common warts market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the common warts market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the common warts market by raising costs of imported dermatological devices, laser treatment systems, pharmaceutical ingredients, and topical formulation components. Hospitals and dermatology clinics in North America and Europe are most impacted due to dependence on imported equipment and specialty medications, while Asia-Pacific faces cost pressures on export-oriented dermatology products. These tariffs are increasing treatment costs and slowing technology upgrades. However, they are also encouraging domestic production of topical therapies and localized manufacturing of dermatology devices.

The common warts market research report is one of a series of new reports that provides common warts market statistics, including common warts industry global market size, regional shares, competitors with a common warts market share, detailed common warts market segments, market trends and opportunities, and any further data you may need to thrive in the common warts industry. This common warts market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Common warts are benign skin growths caused by infection with the human papillomavirus. They most often appear on the hands, fingers, and other exposed areas and develop as the body’s response to the viral infection.

The primary treatment options for common warts include cryotherapy, laser treatment, electrosurgery, and topical medications. Cryotherapy involves the application of extreme cold, usually liquid nitrogen, to freeze and eliminate abnormal tissue. These treatments are used across different patient groups, including children, adults, and elderly individuals. Treatment strategies vary according to the stage of the condition, with specific approaches for early, moderate, and advanced stages. Care is delivered through various end users, including hospitals, dermatology clinics, and home care settings.

The common warts market consists of revenues earned by entities by providing services such as telemedicine consultations, therapy services, and surgical excision. The market value includes the value of related goods sold by the service provider or included within the service offering. The common warts market also includes sales of over-the-counter (OTC) treatments, prescription medications, and medical devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.